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Abstract
Background: There is strong evidence for the use of Enhanced Recovery After Surgery (ERAS) protocol with
colorectal surgery. However, in most studies on ERAS, patients with stage IV colorectal cancer (CRC) are commonly
excluded. It is not certain if the ERAS protocol combined with laparoscopy improves outcomes in this group of
patients as well.
The aim of the study is to assess the feasibility of the ERAS protocol implementation in patients operated
laparoscopically due to stage IV CRC.
Methods: A prospective analysis of patients undergoing laparoscopic colorectal surgery was performed. Group 1
included patients with stages I–III, and group 2 included patients with stage IV CRC. Demographic, surgical factors,
length of stay (LOS), complications, readmissions, ERAS implementation and early postoperative recovery were
compared between the groups.
Results: Group 1 included 168 patients, and group 2 included 20 patients. There was no difference in the age, sex,
BMI, ASA, cancer localisation or surgical parameters. No statistically significant difference was noted in complications
(26.8 vs 20 %, p = 0.51344), LOS (4.7 vs 5.7 days, p = 0.28228) or readmissions (6 vs 10 %, p = 0.48392). The ERAS
protocol compliance was 86.3 and 83.0 %, respectively (p = 0.17158).
Conclusions: Implementation of the ERAS protocol and laparoscopic surgery among patients with stage IV CRC is
feasible and provides similar short-term clinical outcomes and recovery as with patients with stages I–III.
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Background
Over the last 20 years, the perioperative care has im-
proved significantly due to the better understanding of
pathophysiological mechanisms underlying stress re-
sponse to surgery. It was Kehlet who first observed that
minimally invasive surgery together with appropriate an-
algesia, early mobilisation and oral feeding resulted in
better outcomes [1]. Although initially the main goal of
the so called fast-track surgery was to shorten the length
of stay, the most recent concept is more complex—it
aims to attenuate stress response and decrease the nega-
tive influence of insulin resistance in postoperative
period [2, 3]. This in turn results in rapid functional re-
covery which, according to many, is considered the most
important target of the modern perioperative care [4].
The novel Enhanced Recovery After Surgery (ERAS)
philosophy uses multimodal interventions such as the
following: preoperative counselling, no mechanical
bowel preparation, shortening preoperative fasting, bal-
anced fluid therapy, use of laparoscopy and short-acting
anaesthetic agents, appropriate pain control and early
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oral feeding and mobilisation [5, 6]. In contrast to trad-
itional care, ERAS involves multidisciplinary teams of
surgeons, anaesthetists, nurses, dieticians and physio-
therapists. Interestingly, it is the patient who is actively
involved in the treatment process and plays a key role in
it [7]. There is strong evidence for the use of the ERAS
protocol with colorectal cancer surgery [8, 9]. It is also
well-known that adherence to the protocol correlates with
clinical outcomes [10, 11]. However, until now, none of
the studies evaluated the feasibility and effects of the
ERAS protocol implementation in patients with colorectal
cancer (CRC) stage IV, according to the American Joint
Committee on Cancer (AJCC), compared with patients
with stages I–III. In most ERAS-related articles, staging of
cancer is not taken into account. Moreover, stage IV is a
common exclusion criterion from the study [12–14]. It
might be important in the context of previously con-
ducted research in the field of open colorectal surgery,
with traditional perioperative care, where the stage of dis-
ease was found to influence the clinical outcomes [15].
However, it is unknown whether these findings can be
simply transferred to the groups of patients operated lap-
aroscopically and whose perioperative care was based on
the ERAS protocol. Establishing the possibility of ERAS
implementation and analysing its influence on clinical out-
comes can be crucial for this particular group of patients.
The aim of the study was to assess the feasibility and
effects of the ERAS protocol implementation in patients
with stage IV CRC.
Methods
Prospective analysis was conducted on 188 consecutive pa-
tients undergoing laparoscopic colorectal resection from
January 2012 till February 2015. Inclusion criteria were as
follows: age >18 years, elective laparoscopic surgery due to
histologically confirmed CRC and perioperative care based
on ERAS protocol principles. Patients submitted to open
or emergency surgery, with concomitant inflammatory
bowel diseases, or patients whose perioperative care ac-
cording to ERAS protocol was not possible (for instance
due to an immediate postoperative course continued on an
intensive care unit), as well as patients with rectal cancer
operated with endoscopic techniques like transanal endo-
scopic microsurgery (TEM) or transanal total mesorectal
excision (TaTME), were excluded from the study.
A 16-element ERAS protocol was introduced in our
unit in 2012 (Table 1). Mean compliance in patients with
CRC at the present moment is near 85 %.
Patients were divided into two groups according to the
stage of cancer. Group 1 included patients whose CRC
was staged I to III according to the American Joint
Committee on Cancer (AJCC) grading system and who
underwent radical surgical treatment. Group 2 included
patients with stage IV CRC, patients with distant
resectable metastases who underwent colorectal resec-
tion as part of a two-step surgical treatment (intention
to treat) as well as those with disseminated CRC who
underwent palliative colorectal resection. In these pa-
tients, systemic chemotherapy as first-line treatment was
contraindicated due to complications related to the
tumour such as severe anaemia, obvious bleeding or
high risk of full bowel obstruction in the near future.
During the analysed period, 224 patients with CRC
underwent operations. Fifteen patients underwent emer-
gency or primarily open procedure and thus were ex-
cluded from the study. Similarly, 18 patients with rectal
cancer who underwent TEM or TaTME were excluded
from further analysis. Three patients were excluded from
the study due to the necessity of immediate postopera-
tive stay at the intensive care unit, and ERAS protocol
was not applied (Fig. 1).
The age, sex, body mass index (BMI), American Society
of Anaesthesiologists (ASA) scale, localisation of the can-
cer, intraoperative blood loss and conversion rate were
compared between the two groups. The primary outcomes
were the following: length of stay (LOS) in hospital,
Table 1 ERAS protocol used in our unit
1. Preoperative counselling and patient’s education
2. No bowel preparation (oral lavage in the case of low rectal resection
with TME and defunctioning loop ileostomy)
3. Preoperative carbohydrate loading (400 ml of Nutricia preOp® 2 h
prior surgery)
4. Antithrombotic prophylaxis (Clexane® 40 mg sc. starting in the
evening prior surgery)
5. Antibiotic prophylaxis (preoperative cefuroxime 1.5 g +metronidazole
0.5 g i.v. 30–60 min prior surgery)
6. Laparoscopic surgery
7. Balanced intravenous fluid therapy (<2500 ml intravenous fluids
during the day of surgery, less than 150 mmol sodium)
8. No nasogastric tubes postoperatively
9. No drains left routinely for colonic resections, one drain placed for
<24 h in case of TME
10. TAP (transversus abdominis plane) block, epidural anaesthesia in
cases with high risk of conversion
11. Avoiding opioids, multimodal analgesia (oral when
possible—paracetamol 4 × 1 g, ibuprofen 2 × 200 mg, metamizole
2 × 2.5 g, or ketoprofen 2 × 100 mg)
12. Prevention of postoperative nausea and vomiting (PONV)
(dexamethasone 8 mg i.v., ondansetron 8 mg i.v.,
metoclopramide 10 mg i.v.)
13. Postoperative oxygenation therapy (4–6 l/min.)
14. Early oral feeding (oral nutritional supplement 4 h postoperatively,
light hospital diet and oral nutritional supplements on the first
postoperative day, full hospital diet in the second postoperative day)
15. Urinary catheter removal on the first postoperative day
16. Full mobilisation on the first postoperative day (getting out of bed,
going to toilet, walking along the corridor, at least 4 h out of bed)
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number of complications and frequency of readmissions
during 30 days after discharge. The secondary outcome
was compliance with the ERAS protocol. The tertiary out-
come was the level of recovery after operation.
Postoperative complications are presented according
to the 5-grade Clavien-Dindo scale [16, 17]. Compliance
with the ERAS protocol was assessed by calculations of
accomplishment or failure of 13 pre- and perioperative
protocol elements dependent on medical stuff. The level
of recovery after surgery was established basing on the
passage of first stool as well as implementation of the
following elements of the protocol: tolerance of oral diet
on the first postoperative day, mobilisation of the patient
on the day of surgery and no need for postoperative
opioids consumption.
Discharge criteria were the following: full mobilisation,
good tolerance of oral diet, no need for intravenous fluids or
drugs and no complications. Readmission was defined as any
re-hospitalisation within the first 30 days after discharge.
A demographic analysis of both groups is presented in
Table 2.
The study obtained the ethical approval from the local
ethics review committee of the Jagiellonian University,
Krakow (approval number: KBET/53/B/2014) and has
been performed in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki and its
later amendments. Informed consent was obtained from
all patients before surgery.
Statistical analysis was performed with StatSoft STATIS-
TICA v.10. Tests were selected depending on the type of
the variables. For the qualitative variable test, chi-square
was used. In cases of quantitative variables where no nor-
mal distribution was observed, we used the Mann-
Whitney test. For calculations of ordinal variables, as ASA
grade or postoperative complications assessed by the
Clavien-Dindo classification, we also used the Mann-
Whitney test. p < 0.05 was chosen as statistically signifi-
cant. For calculations of mean LOS in hospital, patients
with extreme values (>3 IQR—>20 days, 5 patients—four
from group 1 and one from group 2) were excluded.
Results
No statistically significant difference between groups was
observed for age, sex, BMI, ASA scale, localisation of the
tumour and type of surgery performed. The groups were
not significantly different in the matter of operative time,
intraoperative blood loss and conversion rate (Table 3).
In 45 patients (26.8 %) from group 1 and four patients
(20 %) from group 2, postoperative complications occurred
(p= 0.51344). Although mean and median LOS was differ-
ent between groups, it did not reach the statistically signifi-
cant difference (4.7 ± 2.9 days vs 5.7 ± 3.3 days, median 4 vs.
5 days, p= 0.28228). Readmissions concerned ten patients
from group 1 and two patients from group 2 (6 vs 10 %, p =
0.48392). One patient from group 1 died in the postopera-
tive period. Primary outcomes are presented in Table 4.
Fig. 1 ITT flowchart
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No statistically significant difference between groups was
noted in terms of compliance to the pre- and intraopera-
tive ERAS protocol elements (86.3 ± 13.0 % vs 83.0 ±
11.3 %, p = 0.17158). When separate elements were ana-
lysed, only early urinary bladder catheter removal (<24 h
postoperatively, 86.3 vs 60 %, p = 0.00272) and peritoneal
drainage (used in cases of colonic surgery or >24 h in cases
of TME, 76.8 vs. 45 %, p = 0.00236) were different. The
remaining elements did not differ in a statistically signifi-
cant manner. Regarding early postoperative recovery, our
observation also did not show any statistically significant
difference between the groups in passage of first stool, opi-
oid use, tolerance of oral diet and mobilisation in the first
postoperative day (Table 5).
Discussion
In this study involving patients operated laparoscopically
due to CRC, where perioperative care was based on ERAS
protocol principles, we discovered that complications, pro-
longed LOS and readmissions did not occur more often in
patients with stage IV CRC than in the group of patients
with less advanced stages of cancer. In both groups, com-
pliance with the ERAS protocol was also similar. Addition-
ally, no difference was noted in recovery parameters.
Discussions concerning whether to perform palliative re-
sections in patients with advanced CRC are still going on.
According to some authors, resection of an asymptomatic
tumour can be beneficial [18–20]. Moreover, appropriately
planned operations in patients with disseminated cancer
Table 3 Intraoperative parameters in analysed groups
Parameter Group 1 AJCC stages I–III Group 2 AJCC stage IV p value
Mean operative time, min. ± SD 190.7 ± 60.6 189.8 ± 64.3 0.88045
Median operative time, min (IQR) 180 (140–230) 180 (147–225)
Mean intraoperative blood loss, ml ± SD 89.2 ± 76.1 120 ± 115.2 0.16003
Median intraoperative blood loss, ml (IQR) 50 (50–100) 100 (50–125)
Conversion, n (%) 5 (3.0 %) 1 (5.3 %) 0.62643
Table 2 Demographic analysis of patient groups
Parameter Group 1 AJCC stages I–III Group 2 AJCC stage IV p value
Number of patients, n 168(89.4 %) 20 (10.6 %) –
Females, n (%) 81 (48.2 %) 7 (35 %) 0.26290
Males, n (%) 87 (51.8 %) 13 (65 %)
Mean age, years ± SD 66.3 ± 12.8 65.9 ± 10.5 0.82724
BMI, kg/m2 ± SD 26.3 ± 5.1 25.5 ± 5.6 0.32776
ASA 1, n (%) 6 (3.6 %) – 0.89411
ASA 2, n (%) 98 (58.3 %) 13 (65 %)
ASA 3, n (%) 60 (35.7 %) 7 (35 %)
ASA 4, n (%) 4 (2.4 %) –
Colon, n (%) 119 (70.8 %) 13 (65 %) 0.58972
Rectum, n (%) 49 (29.2 %) 7 (35 %)
AJCC stage I, n (%) 65 (38.7 %) – –
AJCC stage II, n (%) 60 (35.7 %) –
AJCC stage III, n (%) 43 (25.6 %) –
AJCC stage IV, potentially resectable, n (%) – 5 (25 %)
AJCC stage IV, palliative resection, n (%) – 15 (75 %)
Right hemicolectomy, n (%) 62 (36.9 %) 5 (25 %) –
Left hemicolectomy, n (%) 12 (7.1 %) –
Sigmoid resection, n (%) 45 (26.8 %) 6 (30 %)
Total mesorectal excision, n (%) 48 (28.6 %) 4 (20 %)
Hartmann’s operation, n (%) – 4 (20 %)
Abdominoperineal excision, n (%) 1 (0.6 %) 1 (5 %)
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can prevent such life-threatening complications as obstruc-
tion, tumour perforation or anaemia in the event of
chronic bleeding [21, 22]. On the other hand, opponents of
such an approach underline the fact that this kind of treat-
ment of patients with advanced CRC does not prolong sur-
vival [23]. According to EURECCA colorectal consensus
conference, the primary treatment option in the case of
disseminated cancer should be systemic chemotherapy
[24]. There is an opinion that advanced cancer predisposes
to complications like anastomotic leakage or adverse car-
diovascular events [25–27]. It should be emphasised that
patients with distant metastases in our study group were
operated on either with intention to cure (potentially
resectable metastases) or in the situation of complications
related to cancer (chronic anaemia, visible bleeding,
obstructing cancer that might lead to full mechanical ob-
struction in the near future). These patients were disquali-
fied from systemic chemotherapy, and surgery remained
the only possible modality. Our study, however, did not
confirm the hypothesis of worse outcomes in such pa-
tients. There are several possible explanations for that.
First of all, practically all surgeries were performed laparo-
scopically, which is generally associated with a reduced
number of complications [28, 29]. Moreover, the number
of complications in our study is comparable, if not smaller,
with results presented by other centres [30]. It may be ex-
plained by the combination of laparoscopy with the ERAS
protocol. Such synergistic effect is known to decrease the
risk of complications and improve recovery [9, 14, 31].
The majority of publications about the ERAS protocol
and laparoscopy concerns patients with stages I–III CRC.
Available data about patients with stage IV CRC is sparse, as
commonly disseminated cancer is a usual criterion of exclu-
sion from the study [12–14]. What is worth noting is that
we did not observe inferior implementation of ERAS proto-
col in patients with advanced cancer. Compliance to ERAS
protocol was over 80 % in both groups. This confirms the
possibility of the use of ERAS in patients with any stage of
cancer. ERAS implementation allowed patients to reach
comparable recovery, measured by the ability to pass
stool, tolerate oral diet, mobilisation in first postoperative
day and the need for opioids.
Table 4 Postoperative outcomes in analysed groups
Parameter Group 1 AJCC stages I–III Group 2 AJCC stage IV p value
Patients without complications, n (%) 123/168 (73.2 %) 16/20 (80 %) 0.51344
Patients with complications, n (%) 45/168 (26.8 %) 4/20 (20 %)
Clavien-Dindo 1, n (%) 28/168 (16.7 %) – 0.75389
Clavien-Dindo 2, n (%) 6/168 (3.5 %) 1/20 (5 %)
Clavien-Dindo 3, n (%) 10/168 (6 %) 3/20 (15 %)
Clavien-Dindo 5, n (%) 1/168 (0.6 %) –
Mean length of hospital stay, days ± SD 4.7 ± 2.9 5.7 ± 3.3 0.28228
Median length of hospital stay, days (IQR) 4 (3–6) 5 (3–8)
Readmission, n (%) 10 (6 %) 2 (10 %) 0.48392
Mortality within 30 days post-surgery, n (%) 1 (0.6 %) – –
Table 5 Compliance with perioperative parameters in analysed groups
Parameter Group 1 AJCC stages I–III Group 2 AJCC stage IV p value
Selective mechanical bowel preparation 114 (68 %) 16 (80 %) 0.51522
Preoperative CHO-loading 126 (75 %) 16 (80 %) 0.62294
Balanced fluid therapy 139 (82.7 %) 14 (70 %) 0.16652
Urinary catheterisation after surgery <24 h 145 (86.3 %) 12 (60 %) 0.00272
Selective peritoneal drainage 129 (76.8 %) 9 (45 %) 0.00236
Compliance with ERAS protocol, % ± SD 86.3 ± 13.0 83.0 ± 11.3 0.17158
Functional postoperative recovery
Tolerance of full oral diet in the first postoperative day 121 (72 %) 12 (60 %) 0.26385
Full mobilisation on the first postoperative day 147 (87.5 %) 15 (75 %) 0.12582
No need for opioids 106 (63.1 %) 15 (75 %) 0.29339
Passage of first stool, (days, mean, ±SD, median) (1–4 days), 2.29 ± 1.13 days, median
2 days
(0–7 days), 2.23 ± 1.47 days, median
2 days
0.71564
The table presents only selected ERAS protocol elements in which compliance was lower than 95 %
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Our study has certain limitations typical for single-centre
studies. An additional limitation is the relatively small num-
ber of patients recruited to the group with stage IV CRC,
resulting in different group sizes. This can create a risk of
type II error and requires further analysis based on a larger
group of patients. Moreover, we did not assess long-term re-
sults in both groups. This is the subject of our future studies.
Conclusions
A combination of laparoscopy with the ERAS protocol pro-
vides similar short-term outcomes in patients with stage IV
CRC. This can be an argument when deciding whether to
perform palliative resection when surgery in this group of
patients is necessary. Due to the abovementioned limita-
tions, further research on larger groups is required.
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